- Home
- BNKK vs TPST Comparison
BNKK vs TPST Comparison
Compare BNKK & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BNKK | TPST |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9M | 15.2M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | BNKK | TPST |
|---|---|---|
| Price | $2.59 | $2.84 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $12.50 |
| AVG Volume (30 Days) | ★ 325.8K | 98.4K |
| Earning Date | 11-19-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,293,124.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 251.44 | N/A |
| 52 Week Low | $2.33 | $2.80 |
| 52 Week High | $46.90 | $13.65 |
Technical Indicators
Market Signals| Indicator | BNKK | TPST |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 27.00 |
| Support Level | N/A | $2.87 |
| Resistance Level | N/A | $3.20 |
| Average True Range (ATR) | 0.00 | 0.15 |
| MACD | 0.00 | 0.21 |
| Stochastic Oscillator | 0.00 | 15.13 |
Price Performance
Historical ComparisonAbout BNKK Bonk Inc.
Bonk Inc is a publicly traded company focused on building a digital asset treasury centered around the BONK ecosystem on the Solana blockchain. It generates revenue through a recurring interest in the memecoin launchpad letsBONK.fun and actively manages its treasury of BONK tokens.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.